Prevention of Arthritis by Locally Synthesized Recombinant Antibody Neutralizing Complement Component C5

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Durigutto, Paolo ^a   Macor, Paolo ^a   Ziller, Federica ^a   De Maso, Luca ^a   Fischetti, Fabio ^a   Marzari, Roberto ^a   Sblattero, Daniele ^b   Tedesco, Francesco ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; COMPLEMENT COMPONENT C5; LIPOSOME; MB 1222; MUBODINA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIGEN BINDING; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; CELL HYPERPLASIA; CELL INFILTRATION; COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; CONTROLLED STUDY; DNA VECTOR; DRUG DELIVERY SYSTEM; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROSIS; GENE TRANSFER; HISTOPATHOLOGY; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PATHOGENESIS; PROTEIN CLEAVAGE; RAT; VASCULITIS; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, NEUTRALIZING; ARTHRITIS, EXPERIMENTAL; CELL LINE; COMPLEMENT ACTIVATION; COMPLEMENT C5; CRICETINAE; GENETIC VECTORS; HUMANS; INFLAMMATION; INJECTIONS, INTRA-ARTICULAR; MALE; RATS; SHEEP; TRANSFECTION;

EID: 84874731813     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058696     Document Type: Article

References (37)

1. Weyand CM, Fujii H, Shao L, Goronzy JJ, (2009) Rejuvenating the immune system in rheumatoid arthritis. Nat Rev Rheumatol 5: 583-588.
2. Taylor PC, Feldmann M, (2009) Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat Rev Rheumatol 5: 578-582.
3. Senolt L, Vencovsky J, Pavelka K, Ospelt C, Gay S, (2009) Prospective new biological therapies for rheumatoid arthritis. Autoimmun Rev 9: 102-107.
4. Smolen JS, Aletaha D, Grisar JC, Stamm TA, Sharp JT, (2009) Estimation of a numerical value for joint damage-related physical disability in rheumatoid arthritis clinical trials. Ann Rheum Dis 69: 1058-1064.
5. van Vollenhoven RF, (2009) Treatment of rheumatoid arthritis: state of the art 2009. Nat Rev Rheumatol 5: 531-541.
6. Corvetta A, Pomponio G, Rinaldi N, Luchetti MM, Di Loreto C, et al. (1992) Terminal complement complex in synovial tissue from patients affected by rheumatoid arthritis, osteoarthritis and acute joint trauma. Clin Exp Rheumatol 10: 433-438.
7. Hietala MA, Nandakumar KS, Persson L, Fahlen S, Holmdahl R, et al. (2004) Complement activation by both classical and alternative pathways is critical for the effector phase of arthritis. Eur J Immunol 34: 1208-1216.
8. Dimitrova P, Ivanovska N, Belenska L, Milanova V, Schwaeble W, et al. (2012) Abrogated RANKL expression in properdin-deficient mice is associated with better outcome from collagen-antibody induced arthritis. Arthritis Res Ther 14: R173.
9. Banda NK, Hyatt S, Antonioli AH, White JT, Glogowska M, et al. (2012) Role of C3a receptors, C5a receptors, and complement protein C6 deficiency in collagen antibody-induced arthritis in mice. J Immunol 188: 1469-1478.
10. Ji H, Ohmura K, Mahmood U, Lee DM, Hofhuis FM, et al. (2002) Arthritis critically dependent on innate immune system players. Immunity 16: 157-168.
11. Nilsson KE, Andren M, Diaz de Stahl T, Kleinau S, (2009) Enhanced susceptibility to low-dose collagen-induced arthritis in CR1/2-deficient female mice--possible role of estrogen on CR1 expression. FASEB J 23: 2450-2458.
12. Banda NK, Takahashi M, Levitt B, Glogowska M, Nicholas J, et al. (2010) Essential role of complement mannose-binding lectin-associated serine proteases-1/3 in the murine collagen antibody-induced model of inflammatory arthritis. J Immunol 185: 5598-5606.
13. Copland DA, Hussain K, Baalasubramanian S, Hughes TR, Morgan BP, et al. (2010) Systemic and local anti-C5 therapy reduces the disease severity in experimental autoimmune uveoretinitis. Clin Exp Immunol 159: 303-314.
14. Wang Y, Kristan J, Hao L, Lenkoski CS, Shen Y, et al. (2000) A role for complement in antibody-mediated inflammation: C5-deficient DBA/1 mice are resistant to collagen-induced arthritis. J Immunol 164: 4340-4347.
15. Thrall JH, (2005) Prevalence and costs of chronic disease in a health care system structured for treatment of acute illness. Radiology 235: 9-12.
16. Macor P, Durigutto P, De Maso L, Garrovo C, Biffi S, et al. (2012) Treatment of experimental arthritis by targeting synovial endothelium with a neutralizing recombinant antibody to C5. Arthritis Rheum 64: 2559-2567.
17. Valenta R, Niespodziana K, Focke-Tejkl M, Marth K, Huber H, et al. (2011) Recombinant allergens: what does the future hold? J Allergy Clin Immunol 127: 860-864.
18. Marzari R, Sblattero D, Macor P, Fischetti F, Gennaro R, et al. (2002) The cleavage site of C5 from man and animals as a common target for neutralizing human monoclonal antibodies: in vitro and in vivo studies. Eur J Immunol 32: 2773-2782.
19. Di Niro R, Sblattero D, Florian F, Stebel M, Zentilin L, et al. (2008) Anti-idiotypic response in mice expressing human autoantibodies. Mol Immunol 45: 1782-1791.
20. Boscolo S, Mion F, Licciulli M, Macor P, De Maso L, et al. (2012) Simple scale-up of recombinant antibody production using an UCOE containing vector. N Biotechnol 29: 477-484.
21. Hanke T, Szawlowski P, Randall RE, (1992) Construction of solid matrix-antibody-antigen complexes containing simian immunodeficiency virus p27 using tag-specific monoclonal antibody and tag-linked antigen. J Gen Virol (Pt 3) 73: 653-660.
22. Fischetti F, Durigutto P, Macor P, Marzari R, Carretta R, et al. (2007) Selective therapeutic control of C5a and the terminal complement complex by anti-C5 single-chain Fv in an experimental model of antigen-induced arthritis in rats. Arthritis Rheum 56: 1187-1197.
23. Fischetti F, Durigutto P, Pellis V, Debeus A, Macor P, et al. (2005) Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor. Blood 106: 2340-2346.
24. Macor P, Tripodo C, Zorzet S, Piovan E, Bossi F, et al. (2007) In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. Cancer Res 67: 10556-10563.
25. Ziller F, Macor P, Bulla R, Sblattero D, Marzari R, et al. (2005) Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59. Eur J Immunol 35: 2175-2183.
26. Morgan BP, (2000) The complement system: an overview. Methods Mol Biol 150: 1-13.
27. Neumann E, Barnum SR, Tarner IH, Echols J, Fleck M, et al. (2002) Local production of complement proteins in rheumatoid arthritis synovium. Arthritis Rheum 46: 934-945.
28. Ochiya T, Takahama Y, Baba-Toriyama H, Tsukamoto M, Yasuda Y, et al. (1999) Evaluation of cationic liposome suitable for gene transfer into pregnant animals. Biochem Biophys Res Commun 258: 358-365.
29. Gao X, Kim KS, Liu D, (2007) Nonviral gene delivery: what we know and what is next. AAPS J 9: E92-104.
30. Cesco-Gaspere M, Zentilin L, Giacca M, Burrone OR, (2008) Boosting anti-idiotype immune response with recombinant AAV enhances tumour protection induced by gene gun vaccination. Scand J Immunol 68: 58-66.
31. Skaricic D, Traube C, De B, Joh J, Boyer J, et al. (2008) Genetic delivery of an anti-RSV antibody to protect against pulmonary infection with RSV. Virology 378: 79-85.
32. Hackett NR, Kaminsky SM, Sondhi D, Crystal RG, (2000) Antivector and antitransgene host responses in gene therapy. Curr Opin Mol Ther 2: 376-382.
33. Garmory HS, Perkins SD, Phillpotts RJ, Titball RW, (2005) DNA vaccines for biodefence. Adv Drug Deliv Rev 57: 1343-1361.
34. Goodfellow RM, Williams AS, Levin JL, Williams BD, Morgan BP, (1997) Local therapy with soluble complement receptor 1 (sCR1) suppresses inflammation in rat mono-articular arthritis. Clin Exp Immunol 110: 45-52.
35. Linton SM, Morgan BP, (1999) Complement activation and inhibition in experimental models of arthritis. Mol Immunol 36: 905-914.
36. Bliddal H, Terslev L, Qvistgaard E, Konig M, Holm CC, et al. (2006) A randomized, controlled study of a single intra-articular injection of etanercept or glucocorticosteroids in patients with rheumatoid arthritis. Scand J Rheumatol 35: 341-345.
37. Roux CH, Breuil V, Valerio L, Amoretti N, Brocq O, et al. (2011) Etanercept compared to intraarticular corticosteroid injection in rheumatoid arthritis: double-blind, randomized pilot study. J Rheumatol 38: 1009-1011.